SCHEMBL1107430

SCHEMBL1107430

Cc1nc(C=O)cs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5673184 0.79 GRM5 (0.46)
SCHEMBL5673175 0.79 GRM5 (0.46)
SCHEMBL10247442 0.76
SCHEMBL7068854 0.76 KDM4E (0.38)
SCHEMBL7068851 0.76 KDM4E (0.38)
SCHEMBL12333167 0.74
SCHEMBL3446831 0.74
SCHEMBL22708306 0.74
SCHEMBL5227488 0.74 GRM5 (0.36)
SCHEMBL6139938 0.74 KDM4E (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817036-B1 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMA (US) 2012-07-04 EP claimed
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
US-20260098047-A1 Anti-Giardial Compounds COMMW SCIENT IND RES ORG (AU) 2026-04-09 US disclosed
US-12582645-B2 Chemokine CXCR4 receptor modulators and uses related thereto EMORY UNIVERSITY (US) 2026-03-24 US disclosed
EP-4709723-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 EP disclosed
US-20260055113-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2026-02-26 US disclosed
EP-4695242-A1 NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF Meta Pharmaceuticals (HK) Limited (HK) 2026-02-18 EP disclosed
EP-4652160-A1 COMPOUNDS FOR NUCLEIC ACID CLEAVAGE Cambridge Enterprise Limited (GB) 2025-11-26 EP disclosed
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 EP disclosed
US-12370183-B2 Compositions and methods for treating malaria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-07-29 US disclosed
CN-1021046-C PREPARING METHOD FOR NITRIC ESTER DERIVATIVE FUJISAWA PHARMACEUTICAL CO (JP) 1993-06-02 CN disclosed
EP-0239815-B1 SUBSTITUTED THIAZOLES AND OXAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION Dr. Karl Thomae GmbH (DE) 1991-07-24 EP disclosed
US-5010093-A Vasodilators; cardiovascular disorders FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-04-23 US disclosed
US-4923886-A VASODILATORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-05-08 US disclosed
US-4886814-A LOWER BLOOD SUGAR DR. KARL THOMAS GMBH (DE) 1989-12-12 US disclosed
CN-1031226-A Nitrate derivatives FUJISAWA PHARMACEUTICAL CO (JP) 1989-02-22 CN disclosed
EP-0300400-A1 Nitric acid ester derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-01-25 EP disclosed
EP-0239815-A1 Substituted thiazoles and oxazoles, medicines containing these compounds and process for their preparation Dr. Karl Thomae GmbH (DE) 1987-10-07 EP disclosed
US-4380547-A Dihydropyridine compounds which are substituted in the 4-position by imidazolyl or thiazolyl and their medicinal use BAYER AKTIENGESELLSCHAFT (DE) 1983-04-19 US disclosed
US-4226765-A Novel rifamycin compounds of high antibiotic activity ARCHIFAR INDUSTRIE CHIMICHE DEL TRENTINO S.P.A. (IT) 1980-10-07 US disclosed